PMID- 35048805
OWN - NLM
STAT- MEDLINE
DCOM- 20221215
LR  - 20230321
IS  - 1875-5666 (Electronic)
IS  - 1566-5240 (Linking)
VI  - 23
IP  - 1
DP  - 2023
TI  - Breviscapine Combined with BMSCs Reduces Abeta Deposition in Rat with Alzheimer's 
      Disease by Regulating Circular RNA ciRS-7.
PG  - 76-86
LID - 10.2174/1566524022666220113151044 [doi]
AB  - AIMS: This study aimed to clarify that breviscapine combined with bone marrow 
      mesenchymal stem cells (BMSCs) treatment can reduce Abeta deposition in Alzheimer's 
      disease (AD) patients. BACKGROUND: AD is a common degenerative disease of the 
      central nervous system. Abeta protein deposition in the cerebral cortex and 
      hippocampus causes neuronal peroxidation damage, synaptic dysfunction, 
      neuroinflammation, and nerve cell apoptosis, and ultimately leads to AD. 
      OBJECTIVE: To investigate whether breviscapine combined with BMSCs treatment can 
      reduce Abeta deposition in AD. METHODS: The AD rat model was successfully induced by 
      Abeta1-42. The expression of protein and mRNA was detected by western blot and 
      reverse transcription-quantitative PCR (RT-qPCR), respectively. RESULTS: In AD 
      rat brain tissue, the expression of circular RNA ciRS-7 (ciRS-7), ubiquitin 
      carboxyl-terminal hydrolase L1 (UCHL1), and NF-kappaB p65 was significantly 
      downregulated, and the expression of beta-amyloid precursor protein (APP), beta-site 
      APPcleaving enzyme 1 (BAEC1), and Abeta was upregulated. The expression of ciRS-7, 
      UCHL1, and p65 was significantly upregulated after breviscapine or BMSCs 
      treatment, and there was increased APP and BAEC1 degradation. Notably, 
      breviscapine combined with BMSCs treatment was more effective than either 
      treatment alone. In SH-SY5Y cells, overexpression of ciRS-7 reduced Abeta deposition 
      by upregulating UCHL1 to degrade APP and BAEC1, but these effects were reversed 
      with inhibition of NF-kB signaling. Finally, knockdown of ciRS-7 elevated Abeta, 
      APP, and BAEC1 expression in each group of rats compared with the control. 
      CONCLUSION: Breviscapine combined with BMSCs treatment can reduce Abeta deposition 
      in AD rats and promote the degradation of APP and BAEC1 by activating NF-kB to 
      promote UCHL1 expression.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Sun, Fengqin
AU  - Sun F
AD  - Department of Neurology, The Third People's Hospital of Yunnan Province, 292 
      Beijing Road, Kunming, 650011, China.
FAU - Zhang, Yulin
AU  - Zhang Y
AD  - Department of Neurology, The Third People's Hospital of Yunnan Province, 292 
      Beijing Road, Kunming, 650011, China.
FAU - Wu, Xinran
AU  - Wu X
AD  - Teaching Research Department, The Third People's Hospital of Yunnan Province, 292 
      Beijing Road, Kunming, 650011, China.
FAU - Xu, Xu
AU  - Xu X
AD  - Department of Neurology, The Third People's Hospital of Yunnan Province, 292 
      Beijing Road, Kunming, 650011, China.
FAU - Zhu, Chaodie
AU  - Zhu C
AD  - Department of Neurology, The Third People's Hospital of Yunnan Province, 292 
      Beijing Road, Kunming, 650011, China.
FAU - Huang, Wei
AU  - Huang W
AD  - Department of Neurology, The Third People's Hospital of Yunnan Province, 292 
      Beijing Road, Kunming, 650011, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Curr Mol Med
JT  - Current molecular medicine
JID - 101093076
RN  - 0 (RNA, Circular)
RN  - 0 (NF-kappa B)
SB  - IM
MH  - Humans
MH  - Animals
MH  - Rats
MH  - *Alzheimer Disease/genetics/therapy
MH  - RNA, Circular/genetics
MH  - NF-kappa B/genetics
MH  - *Neuroblastoma
MH  - *Mesenchymal Stem Cells
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Abeta deposition
OT  - bone marrow mesenchymal stem cells
OT  - breviscapine
OT  - circular RNA ciRS-7
EDAT- 2022/01/21 06:00
MHDA- 2022/12/15 06:00
CRDT- 2022/01/20 08:49
PHST- 2021/05/01 00:00 [received]
PHST- 2021/11/05 00:00 [revised]
PHST- 2021/11/25 00:00 [accepted]
PHST- 2022/01/21 06:00 [pubmed]
PHST- 2022/12/15 06:00 [medline]
PHST- 2022/01/20 08:49 [entrez]
AID - CMM-EPUB-120171 [pii]
AID - 10.2174/1566524022666220113151044 [doi]
PST - ppublish
SO  - Curr Mol Med. 2023;23(1):76-86. doi: 10.2174/1566524022666220113151044.